Metrics

The numbers behind Pfizer Inc.: as-reported financial statements and company metrics for FY2021–FY2025, traced to the source filings, opened with the share-price history those statements have to justify. Every linked figure opens the exact page of the filing it was printed on, with the statement row highlighted. Amounts in US$ millions unless noted.

Reading notes: Display units: US$ millions, except per-share (US$) and share counts (millions), as printed on the consolidated statements. Fiscal year ends December 31. Revenue components: FY2021–FY2022 are shown as reported in the FY2023 10-K, which lined only Product and Alliance revenues (royalty income was not separately presented), so the Royalty revenues row is blank for those years. FY2023–FY2025 include the separate Royalty revenues line introduced in the FY2024 10-K; on that basis Total revenues were recast upward by the royalty amount (FY2023: $58,496M - $59,553M). Revenue by Therapeutic Area: FY2023–FY2025 come from the FY2025 10-K (Note 17, recast basis); FY2021–FY2022 come from the FY2023 10-K (original basis). Because of the FY2023 recast, the FY2023 category figures shown here (e.g., Primary Care $30,799M) differ slightly from the FY2023 10-K's original presentation ($30,589M). Pfizer Ignite is being wound down (discontinued in 2025). Balance sheet prints two years per 10-K: FY2021 is sourced from the FY2022 10-K, FY2022–FY2023 from the FY2023 10-K, FY2024–FY2025 from the FY2025 10-K. 'Trade accounts receivable, net' and 'Property, plant and equipment' / 'Identifiable intangible assets' appear with a '(net)' suffix in the FY2025 10-K and without it in earlier filings; labels are harmonized here.

Share Price — Full Available History — 37 Years

The stock closed at $24.64 on Jul 24, 2026 — up 22,160% over the window shown (+15.9% a year), trading between $0.09 and $61.25. At that close the stock trades at 18× FY2025 diluted EPS as reported below.

Source: market price feed, monthly closes, sampled from 9,208 source observations, Jan 1990–Jul 2026. Price return only, excludes dividends. Prices are split-adjusted (1:2 on Apr 01, 1991; 1:2 on Jul 03, 1995; 1:2 on Jul 01, 1997; 1:3 on Jul 01, 1999; ×1.054 on Nov 17, 2020).

Market capitalization $151.8bn and enterprise value $215.3bn.

Market cap = 6.16B shares outstanding × the Jul 24, 2026 close of $24.64. Enterprise value adds total debt of $64.6bn and subtracts cash and equivalents of $1.1bn (net debt of $63.5bn), from the FY2025 balance sheet. Market-derived figures, shown without filing links.

FY2025 at a Glance

Source: FY2025 consolidated statements [1] [2]. Click any linked figure to open the filing page with the row highlighted.

Revenue by Therapeutic Area

Revenue by Therapeutic Area	FY2021	FY2022	FY2023	FY2024	FY2025
Primary Care	52,029	73,023	30,799	30,135	26,820
Specialty Care	15,194	13,833	14,988	16,652	17,546
Oncology	12,333	12,132	12,450	15,612	16,834
Biopharma	79,557	98,988	58,237	62,400	61,199
Pfizer CentreOne	1,731	1,335	1,272	1,146	1,338
Pfizer Ignite	0	7	44	82	41
Total revenues	81,288	100,330	59,553	63,627	62,579
Total revenues growth, derived	—	+23.4%	-40.6%	+6.8%	-1.6%

Source: Note 17 Segment, Geographic and Other Revenue Information — Significant Revenues by Product [3] [4] [5]. Click any linked figure to open the filing page with the row highlighted.

Income Statement

Source: Consolidated Statements of Operations [1] [2]. Click any linked figure to open the filing page with the row highlighted.

Columns marked E are consensus analyst estimates from S&P Capital IQ (CapIQ), shown alongside reported results for direct comparison; they are not company guidance.

Estimate source: S&P Capital IQ (CapIQ) consensus, as of 2026-07-27. Estimate figures are S&P Capital IQ consensus (vendor data — no filing page links). EPS and net income use the normalized (adjusted) consensus where the street reports it. Line-item analyst models (segments, drivers, KPIs) are in the Visible Alpha tab.

Balance Sheet

Source: Consolidated Balance Sheets [6] [7] [8]. Click any linked figure to open the filing page with the row highlighted.

Cash Flow

Source: Consolidated Statements of Cash Flows [9] [10]. Click any linked figure to open the filing page with the row highlighted.

Blockbuster Franchises — Significant Revenues by Product

Blockbuster Franchises — Significant Revenues by Product	FY2021	FY2022	FY2023	FY2024	FY2025
Comirnaty (COVID-19 vaccine)	36,781	37,806	11,220	5,353	4,367
Paxlovid	76	18,933	1,279	5,716	2,362
Eliquis	5,970	6,480	6,747	7,366	7,961
Prevnar family	5,272	6,337	6,501	6,411	6,494
Vyndaqel family	2,015	2,447	3,321	5,451	6,380
Ibrance	5,437	5,120	4,753	4,367	4,122

Source: company filings [3] [5]. Click any linked figure to open the filing page with the row highlighted.

Growth Drivers Oncology — Product Revenues

Growth Drivers Oncology — Product Revenues	FY2021	FY2022	FY2023	FY2024	FY2025
Nurtec ODT/Vydura	—	213	928	1,263	1,424
Abrysvo (RSV vaccine)	—	—	890	755	1,033
Padcev	—	—	53	1,588	1,940
Xtandi	—	—	1,659	2,039	2,194
Xeljanz	2,455	1,796	1,703	1,168	1,087
Lorbrena	266	343	539	731	1,023

Source: company filings [3] [5]. Click any linked figure to open the filing page with the row highlighted.

Revenue by Geography

Revenue by Geography	FY2021	FY2022	FY2023	FY2024	FY2025
United States revenue	29,746	42,473	28,145	38,691	37,078
Emerging Markets revenue	20,701	20,097	10,498	8,879	9,313
Developed Markets revenue	—	—	20,910	16,057	16,188

Source: company filings [11] [12]. Click any linked figure to open the filing page with the row highlighted.

Non-GAAP Profitability, Capital Returns Workforce

Non-GAAP Profitability, Capital Returns Workforce	FY2021	FY2022	FY2023	FY2024	FY2025
Adjusted diluted EPS (non-GAAP)	4.06	6.58	1.84	3.11	3.22
Adjusted income (non-GAAP)	23,196	37,717	10,501	17,716	18,406
Adjusted effective tax rate (non-GAAP)	14.5%	11.7%	9.0%	14.5%	12.7%
Cash dividends declared per share	1.57	1.61	1.65	1.69	1.72
Employees (worldwide, year-end)	79,000	83,000	88,000	81,000	75,000

Source: company filings [13] [14] [15] [16]. Click any linked figure to open the filing page with the row highlighted.

Long-Term Record

Fiscal year	Total revenue	Net income	Diluted EPS	Operating cash flow	Capital expenditures
FY2019	40,905	16,026	2.82	12,588	2,046
FY2020	41,651	9,159	1.63	14,403	2,226
FY2021	81,288	21,979	3.85	32,580	2,711
FY2022	100,330	31,372	5.47	29,267	3,236
FY2023	59,553	2,119	0.37	8,700	3,907
FY2024	63,627	8,031	1.41	12,744	2,909
FY2025	62,579	7,771	1.36	11,704	2,629

Source: consolidated statements across filings; older years from the standardized feed [9] [1] [10] [2]. Click any linked figure to open the filing page with the row highlighted.

Analyst Consensus

Street ratings: 8 strong buy, 2 buy, 16 hold, 1 sell, 1 strong sell. Consensus: Buy.

Estimate source: S&P Capital IQ (CapIQ) consensus, as of 2026-07-27. Estimate figures are S&P Capital IQ consensus (vendor data — no filing page links). EPS and net income use the normalized (adjusted) consensus where the street reports it. Line-item analyst models (segments, drivers, KPIs) are in the Visible Alpha tab.

Traceability

399 of 399 figures on this page (100%) link to the filing page where they are printed — click a linked figure to open the source PDF at that page with the row highlighted. Unlinked figures come from standardized data feeds or pre-filing years.

• Display units: US$ millions, except per-share (US$) and share counts (millions), as printed on the consolidated statements. Fiscal year ends December 31.

• Revenue components: FY2021–FY2022 are shown as reported in the FY2023 10-K, which lined only Product and Alliance revenues (royalty income was not separately presented), so the Royalty revenues row is blank for those years. FY2023–FY2025 include the separate Royalty revenues line introduced in the FY2024 10-K; on that basis Total revenues were recast upward by the royalty amount (FY2023: $58,496M - $59,553M).

• Revenue by Therapeutic Area: FY2023–FY2025 come from the FY2025 10-K (Note 17, recast basis); FY2021–FY2022 come from the FY2023 10-K (original basis). Because of the FY2023 recast, the FY2023 category figures shown here (e.g., Primary Care $30,799M) differ slightly from the FY2023 10-K's original presentation ($30,589M). Pfizer Ignite is being wound down (discontinued in 2025).

• Balance sheet prints two years per 10-K: FY2021 is sourced from the FY2022 10-K, FY2022–FY2023 from the FY2023 10-K, FY2024–FY2025 from the FY2025 10-K. 'Trade accounts receivable, net' and 'Property, plant and equipment' / 'Identifiable intangible assets' appear with a '(net)' suffix in the FY2025 10-K and without it in earlier filings; labels are harmonized here.

• Long-Term Record FY2019–FY2020 are the continuing-operations columns of the FY2021 10-K (after the 2019 Consumer Healthcare JV and the November 2020 Upjohn/Viatris separation) and are not comparable to Pfizer's originally reported pre-2019 totals. Capital expenditures are shown as positive magnitudes of the printed 'Purchases of property, plant and equipment' outflow.

• 6 figure(s) differed between the data feed and the filing; the filing value is shown (see the run's metrics/metrics_tab.json for the audit trail).